Search

Your search keyword '"Florence I"' showing total 1,337 results

Search Constraints

Start Over You searched for: Author "Florence I" Remove constraint Author: "Florence I"
1,337 results on '"Florence I"'

Search Results

1. Exposing 24-hour cycles in bile acids of male humans

2. Discovering cell-active BCL6 inhibitors: effectively combining biochemical HTS with multiple biophysical techniques, X-ray crystallography and cell-based assays

3. Nutrient-rich submarine groundwater discharge increases algal carbon uptake in a tropical reef ecosystem

4. FGF7–FGFR2 autocrine signaling increases growth and chemoresistance of fusion‐positive rhabdomyosarcomas

5. Presence of human breast cancer xenograft changes the diurnal profile of amino acids in mice

6. Effects of Congenital Blindness on Ultrasonic Vocalizations and Social Behaviors in the ZRDBA Mouse

7. 26th Annual Computational Neuroscience Meeting (CNS*2017): Part 3

9. A Novel μCT Analysis Reveals Different Responses of Bioerosion and Secondary Accretion to Environmental Variability.

10. Excitatory and inhibitory STDP jointly tune feedforward neural circuits to selectively propagate correlated spiking activity

11. Patterns in temporal variability of temperature, oxygen and pH along an environmental gradient in a coral reef.

12. A Phase I/II Study of a 72-h Continuous Infusion of Etoposide in Advanced Soft Tissue Sarcoma

13. Effects of oscillatory flow on fertilization in the green sea urchin Strongylocentrotus droebachiensis.

14. Communication impairments in mice lacking Shank1: reduced levels of ultrasonic vocalizations and scent marking behavior.

15. Development and characterization of a novel variant of long-acting bovine follicle-stimulating hormone (brscFSH)

16. International Ring Trial of a High Resolution Targeted Metabolomics and Lipidomics Platform for Serum and Plasma Analysis

17. Discovering cell-active BCL6 inhibitors: effectively combining biochemical HTS with multiple biophysical techniques, X-ray crystallography and cell-based assays

20. Design, Synthesis, and Evaluation of Inhibitors of Hedgehog Acyltransferase

22. C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-ones: Studies towards the identification of potent, cell penetrant Jumonji C domain containing histone lysine demethylase 4 subfamily (KDM4) inhibitors, compound profiling in cell-based target engagement assays

23. SECURING WOMEN'S EDUCATION FOR SUSTAINABLE ECONOMIC DEVELOPMENT IN RIVERS STATE.

24. EE746 Cost-Effectiveness of Vaccination Strategies to Control Future Mpox Outbreaks in England

25. Contributors

28. Discovery of an In Vivo Chemical Probe for BCL6 Inhibition by Optimization of Tricyclic Quinolinones

29. HSF1 Pathway Inhibitor Clinical Candidate (CCT361814/NXP800) Developed from a Phenotypic Screen as a Potential Treatment for Refractory Ovarian Cancer and Other Malignancies

31. Deployment of an e-Infrastructure for Academic Research

33. Attrition in Psychotherapy: A Survival Analysis

36. Discovery of an In Vivo Chemical Probe for BCL6 Inhibition by Optimization of Tricyclic Quinolinones

37. HSF1 Pathway Inhibitor Clinical Candidate (CCT361814/NXP800) Developed from a Phenotypic Screen as a Potential Treatment for Refractory Ovarian Cancer and Other Malignancies

38. Data from Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers

39. Supplementary Figure 1 from Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation

40. Figure S6 from Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in PIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers

41. Data from The Aurora Kinase Inhibitor CCT137690 Downregulates MYCN and Sensitizes MYCN-Amplified Neuroblastoma In Vivo

42. Supplementary Figure S1 from High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers

43. Data from Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non–BRCA1/2-Mutant Cancers

44. Supplementary Tables S1-S4 from Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers

45. Supplementary Figure 1 from Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma

46. Supplementary Figure Legends 1-5 from The Aurora Kinase Inhibitor CCT137690 Downregulates MYCN and Sensitizes MYCN-Amplified Neuroblastoma In Vivo

47. Supplementary Table 3 from Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation

48. Supplementary Table S1 from High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers

49. Supplementary Data from Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non–BRCA1/2-Mutant Cancers

50. Supplementary Note from Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers

Catalog

Books, media, physical & digital resources